iodine-131

(redirected from I-131)
Also found in: Thesaurus, Medical, Encyclopedia.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.iodine-131 - heavy radioactive isotope of iodine with a half-life of 8 days; used in a sodium salt to diagnose thyroid disease and to treat goiter
radioisotope - a radioactive isotope of an element; produced either naturally or artificially
atomic number 53, I, iodin, iodine - a nonmetallic element belonging to the halogens; used especially in medicine and photography and in dyes; occurs naturally only in combination in small quantities (as in sea water or rocks)
References in periodicals archive ?
As of August 21, 2017, 45,447 DACA recipients have been approved for advance parole through an I-131 Application for travel documents.
The report European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020, analyzes and studies the major market drivers, restraints, challenges, and opportunities.
La OMS (Organizacion Mundial de la Salud) y otros grupos como la ATA (American Thyroid Association) lo clasifican dentro del grupo de tumores diferenciados foliculares de tiroides dentro de las guias de manejo y seguimiento; otros como la AFIP (Armed Forces Institute of Pathology) sugieren clasificarlo como otro tipo de tumor tiroideo y en contraste, la NCCN (National Comprehensive Cancer Network) dedica un capitulo aparte a los carcinomas papilares, foliculares (que son avidos por I-131 y por lo tanto suceptibles de tratamiento) y del anaplasico (no avido por I-131 y no suceptible de tratamiento) para manejo propio del CCH, debido probablemente a su mayor agresividad comparado con los otros tipos de carcinomas diferenciados de tiroides.
A parole application (Form I-131, Application for Travel Document) along with the required fee (or fee waiver request) for each relative to be considered for parole; and
USPRwire, Mon Mar 21 2016] North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020
The prognostic factors described in this system include incomplete tumor resection, aggressive histology subtypes, tumor invasion, cervical lymph node metastasis, distant metastasis and I-131 uptake outside the thyroid bed on whole-body scans (WBSs) undertaken after thyroid remnant ablation.
Available radionuclide therapy in oncology Radionuclide Physical Emission Maximum Radiopharmaceutical half-life range (mm) (days) I-131 8.
17/5/95: Captacion de I-131 a las 2 h 12,9%, a las 24 h 66%, a las 48 h 65,8%; captacion tiroidea Tc-99m a los 20 minutos 47,5%; gammagrafia de tiroides con Tc-99m, bocio difuso hipercaptador, glandula de 60 a 70 g (figura 1).
In a study comparing plasma clearance and renograms of Tc-99m MAG3 with I-123 and I-131 OIH, differential functions obtained from Tc-99m MAG3 and I-123 OIH scintigraphies parenchymal transit time indexes were correlated.
Iodine-131, known as I-131, is a radioactive isotope commonly released after nuclear power plant disasters.
Radioactive iodine-131 (I-131) therapy is generally not effective in treating patients with AIT, because of hypersaturated iodine pool prevents sufficient thyroidal uptake of the I-131.
Depending on the method by which it is absorbed and the length of time it remains in the body, radioactive I-131 is capable of damaging living cells.